Finasteride, an inhibitor of 5 alpha-reductase, suppresses prostatic dihydrotestosterone in men with benign prostatic hyperplasia.

doi:10.1210/JCEM.74.3.1371291

Paper

Finasteride, an inhibitor of 5 alpha-reductase, suppresses prostatic dihydrotestosterone in men with benign prostatic hyperplasia.

Published Mar 1, 1992 · J. Mcconnell, Jean D. Wilson, F. George

The Journal of clinical endocrinology and metabolism

Q1 SJR score

323

Citations

7

Influential Citations

Full textSemantic Scholar

Abstract

The oral administration of finasteride, a 4-aza-steroid inhibitor of 5 alpha-reductase, decreases serum dihydrotestosterone levels, but has little effect on serum testosterone. The current study was designed to assess the effect of finasteride on dihydrotestosterone levels in the prostates of men with benign prostatic hyperplasia. In a double blind, placebo-controlled study, 69 men with symptomatic prostatic hyperplasia were treated with placebo or 1, 5, 10, 50, or 100 mg/day finasteride for 7 days before transurethral resection of the prostate. In the placebo group the mean concentration of prostatic dihydrotestosterone was 10.3 +/- 0.6 nmol/kg (+/- SE), and the mean concentration of testosterone was 0.7 +/- 0.1 nmol/kg. After 7 days of treatment with all doses of finasteride, prostatic dihydrotestosterone declined to 15% or less of control levels, and the testosterone concentration increased in a reciprocal fashion. Compared to the placebo group, there was no significant difference in the mean prostatic dihydrotestosterone level achieved in any of the finasteride-treated groups. However, prostatic dihydrotestosterone levels were lower in the groups receiving higher doses of the drug. In two additional patients, finasteride treatment for 2 days also caused a decrease in prostatic dihydrotestosterone levels. No significant adverse experiences occurred during the study. We conclude that finasteride causes profound decrease in prostatic dihydrotestosterone.

RCT

Highly Cited

Study Snapshot

Finasteride effectively decreases prostatic dihydrotestosterone levels in men with benign prostatic hyperplasia, while increasing testosterone levels in a reciprocal fashion.

PopulationOlder adults (50-71 years)

Sample size24

MethodsObservational

OutcomesBody Mass Index projections

ResultsSocial networks mitigate obesity in older groups.

Sign up to use Study Snapshot

Consensus is limited without an account. Create an account or sign in to get more searches and use the Study Snapshot.

Create an account

Paper

Finasteride, an inhibitor of 5 alpha-reductase, suppresses prostatic dihydrotestosterone in men with benign prostatic hyperplasia.

Sign up to use Study Snapshot

References

The Clinical Effects of a 5α-Reductase Inhibitor, Finasteride, on Benign Prostatic Hyperplasia

Finasteride effectively reduces prostate volume and improves urinary flow in patients with benign prostatic hyperplasia.

Effect of finasteride, a 5 alpha-reductase inhibitor on prostate tissue androgens and prostate-specific antigen.

Finasteride significantly lowers DHT levels in prostate tissue, but may have a modest residual androgenic effect due to its effect on tissue testosterone.

Effects of finasteride (MK-906), a 5 alpha-reductase inhibitor, on circulating androgens in male volunteers.

Finasteride is well-tolerated by normal male volunteers and significantly suppresses serum dihydrotestosterone at all doses tested, with testosterone levels increasing at 50- and 100-mg doses.

Three-month treatment with a long-acting gonadotropin-releasing hormone agonist of patients with benign prostatic hyperplasia: effects on tissue androgen concentration, 5 alpha-reductase activity and androgen receptor content.

Long-acting GnRH agonist treatment reduces intraprostatic testosterone levels to one-fourth and DHT and 3 alpha-diol levels to one-tenth of untreated men, but may not completely abolish intraprostatic androgen concentrations in metastatic prostatic cancer patients.

5α-Reductase inhibitory and anti-androgenic activities of some 4-azasteroids in the rat

4-azasteroids exhibit anti-androgenic effects against testosterone propionate, with some showing greater activity than dihydrotestosterone propionate, due to inhibition of 5-reductase.

Citations

In vitro 5α-reductase inhibition by selected Ayurvedic herbs for androgenic disorders

Select Ayurvedic herbs possess significant 5-reductase inhibitory properties, with Eclipta alba showing the highest potential for managing androgenic alopecia.

The impact of preoperative 5-alpha reductase inhibitors on functional outcomes and health-related quality of life following radical prostatectomy – A propensity score matched longitudinal study

Preoperative 5-alpha reductase inhibitors (pre-RP 5-ARI) can impair long-term urinary function recovery after radical prostatectomy.

The Efficacy of Cyclooxygenase-2 Inhibitors for the Male Treatment of Lower Urinary Tract Symptoms: A Systematic Review and Meta-Analysis

COX-2 inhibitors are an effective treatment for lower urinary tract symptoms in male patients, improving symptoms without significantly affecting prostate-specific antigen or total prostate volume.

Therapeutic role of Glycyrrhiza Uralensis fisher on benign prostatic hyperplasia through 5 alpha reductase regulation and apoptosis.

Glycyrrhiza uralensis Fischer extract reduces benign prostatic hyperplasia development by inhibiting androgen receptors and activating apoptosis, offering a safer alternative for BPH treatment without affecting sperm count.

5-alpha reductase inhibitors and prostate cancer mortality among men with regular access to screening and health care.

Men using 5-alpha reductase inhibitors are less likely to be diagnosed with low-risk prostate cancer without increasing long-term risk of lethal prostate cancer or cancer-specific death after diagnosis.

Alcohol and Prostate Cancer: Time to Draw Conclusions

High alcohol intake, especially binge drinking, is associated with increased risk of prostate cancer and may accelerate tumor growth, necessitating immediate quitting for patients diagnosed with prostate cancer.

Inhibition of testosterone-mediated benign prostatic enlargement of orchiectomized Sprague-Dawley rats by diets supplemented with bio-elicited peanut sprout powder (BPSP) and three new BPSP-extracted natural compounds identified

Dietary supplements containing bio-elicited peanut sprout powder (BPSP) effectively inhibit testosterone-mediated benign prostatic enlargement in rats, with potential benefits for prostate health.

Phytochemicals With Anti 5-alpha-reductase Activity: A Prospective For Prostate Cancer Treatment

Phytochemicals, such as phytosterols, polyphenols, and fatty acids, show potential as alternative prostate cancer treatments with favourable side effects and less toxic profiles compared to current 5-alpha-reductase inhibitors.

Early Antiandrogen Therapy With Dutasteride Reduces Viral Shedding, Inflammatory Responses, and Time-to-Remission in Males With COVID-19: A Randomized, Double-Blind, Placebo-Controlled Interventional Trial (EAT-DUTA AndroCoV Trial – Biochemical)

Dutasteride treatment reduces viralshedding, inflammation, and time-to-remission in males with COVID-19, improving clinical recovery and overall health outcomes.